In the case of treatment-related complications, CRS and neurotoxicity constitute the notable adverse reactions observed after treatment using CD19/CD3 and CD20/CD30 BSABs for B-ALL and NHL. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.